65,437 trials
Human Papillomavirus (HPV)-Related Malignancies · Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
Primary: Radiographic Responses, Determined by RECIST 1.1 Criteria — 5; 4; 3 Participants
Breast Cancer
Primary: (Phase A Only) Selection of Dose of LUM015 to be Used in Future Breast Trials — 2.1; 4.7; 4.2 Ratio
Ovarian Cancer · Cervical Cancer · Endometrial Cancer
Primary: Number of Participants With Dose-limiting Toxicities (DLTs) for Dose-escalation Part — 0; 0; 0; 0 Participants
First Line Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in…
Coronavirus Disease 2019
Primary: Mean Change From Baseline in Total Symptom Score — -3.4; -3.5 units on a scale — p=0.818
MDD
Primary: Depression Severity Changes Scored From Patient Health Questionnaire (PHQ9) — 5; 6.71; 8.14; 9.14 score on a scale
Vaginal Atrophy
Primary: Vulvovaginal Symptoms Questionnaire — 8; 7.88; 5.93; 5.93 score on a scale
Lumbar Spine Degeneration
Primary: Postoperative Opioid Utilization — 4.82; 9.17 morphine milligram equivalents
Jawline Definition
Primary: Percentage of Participants Who Show ≥ 1-point Jawline Improvement on Both Sides From Baseline on the Allergan Loss of Jawline Definition Scale (ALJDS) — 38.0; 69.0…
Non-Erosive Gastro-Esophageal Reflux Disease · Heartburn
Primary: Percentage of Evaluable Heartburn Episodes Completely Relieved Within 3 Hours and With No Further Heartburn Reported for 24 Hours After Taking Study Drug — 56.0; 60.6…
Diastolic Heart Failure
Primary: Change From Baseline in Treadmill Exercise Time at Maintenance Phase Week 24 — 424.5; 485.0; 89.5; 37.0 Seconds — p=0.0302
Smoking · Pain · Smoking Cessation
Primary: Number of Participants Who Abstained From Smoking Cigarettes at 6months (Prolonged Abstinence) — 43; 41 Participants
Cerebral Vasospasm
Primary: Procedural Success — 64 Vessels Treated
Stress Disorders, Post-Traumatic · Substance-Related Disorders
Primary: Clinician-Administered Posttraumatic Stress Disorder Scale for DSM-5 — 16.5; 18.5 score on a scale
Pancreatic Cancer Metastatic
Primary: Overall Survival (OS) — 11.10; 11.73 months